Loading...
•
Dec 31, 2023
Nektar Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Takeaways
Nektar Therapeutics reported Q4 2023 financial results, with revenue increasing to $23.9 million compared to $22.0 million in Q4 2022. The company's cash and investments in marketable securities were $329.4 million as of December 31, 2023, expected to support operations into Q3 2026. Net loss for the quarter was $42.1 million, an improvement from the $59.7 million loss in the same period last year.
Revenue increased to $23.9 million in Q4 2023 from $22.0 million in Q4 2022.
Cash and investments in marketable securities totaled $329.4 million as of December 31, 2023.
Total operating costs and expenses decreased to $57.4 million in Q4 2023 from $74.5 million in Q4 2022.
Net loss improved to $42.1 million in Q4 2023 from $59.7 million in Q4 2022.
Nektar
Nektar
Forward Guidance
Nektar expects cash and marketable securities to support strategic development activities and operations into the third quarter of 2026.